KANT Projected Dividend Yield
Kineta Inc ( OTCBB : KANT )Kineta, Inc. is a clinical-stage biotechnology company. Co. has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. 21 YEAR PERFORMANCE RESULTS |
KANT Dividend History Detail KANT Dividend News KANT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |